Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, November 2014

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 136 Dimensions

Readers on

mendeley: 104 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 2,571 followers.

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with... http://t.co/Wq3r4Z0SiU

Reply Repost Favourite